The scientific program included 15-20 poster presentations by young scientists following the abstract selection process. Abstracts concentrating on novel pathophysiological aspects of Heart Failure with Preserved Ejection Fraction, and based on original experimental and/or clinical observations would be appreciated.
Friday 23 September12:00 - 18:00 Arrival, Registration18.00-18.20 Welcome address Zoltán Papp, Burkert Pieske, Piotr Ponikowski18.20-19.40 Session I: Ventriculo-Arterial coupling Chairs: Piotr Ponikowski, Paolo N. Marino, Stefan D. Anker18.20-18.40 Ventricular properties and ventriculo-vascular coupling in an animal model of HFPEF and similarities/dys-similarities to observations in humans Daniel Burckhoff18.40-19.00 The role of arterial stiffness and ventriculo-vascular coupling in HFPEF Vojtech Melenovsky19.00-19.20 Asymmetry and dyssynchrony of ventriculo-arterial coupling - a target for treatment? Alan G. Fraser19.20-19.40 Myocardial mechanics in diastole, and wall-motion - blood-flow interaction Jens-Uwe Voigt Discussant Gilles De Keulenaer, Erwan DonalSaturday 24 September08.00-10.00 Session II: Myocardial function, cardiomyocytes and myofilaments Chairs: Burkert Pieske, Ger Stienen08.00-8.20 Hypertrophic cardiomyopathy - a model for HFPEF Thomas Eschenhagen08.20-8.40 Heterogeneity of cellular remodeling in ischemic cardiomyopathy Karin Sipido08.40-9.00 Molecular mechanisms governing functional and structural changes in the pressure-overloaded human heart Stefan Janssens09.00-9.20 Cardiomyocyte dysfunction in HFPEF: the role of myofilament protein alterations Attila Borbély09.20-9.40 Phosphorylation of titin as an important determinant of myocardial passive stiffness Wolfgang Linke09.40-10.00 Mechanisms of LV lengthening velocity - is it only about diastolic function? Otto Smiseth Discussants Franck Rademakers10.00-10.20 Break 10.20-12.20 Session III: Neurohumoral signaling Chairs: Andrew Coats, Heikki Ruskoaho10.20-10.40 Acute neurohumoral modulation of diastolic function Adelino Leite-Moreira10.40-11.00 Paracrine regulators in diastolic dysfunction István Szokodi11.00-11.20 Cell-specific role of NADPH oxidases in diastolic dysfunction Ajay Shah11.20-11.40 Mitochondrial redox regulation and myocardial remodelling Cristoph Maack11.40-12.00 Low myocardial protein kinase G activity in HFPEF: causes and consequences Walter Paulus12.00-12.20 Pro-hypertrophic signaling and diastolic dysfunction Leon De Windt Discussants Rodolphe Fischmeister, Michael Fu 12.20-14.00 Lunch 14.00-16.00 Session IV: Exercise testing and clinical data Chair: Dirk Brutsaert, Alan G. Fraser14.00-14.20 Cardiovascular reserve function with exercise in HFPEF Barry Borlaug14.20-14.40 The role of invasive exercise hemodynamics in the diagnosis of HFPEF David Kaye14.40-15.00 Effects of exercise training on cardiac remodeling and dysfunction: Importance of the underlying pathology Dirk J. Duncker15.00-15.20 HFPEF in the Heart Failure Pilot Survey (ESC-HF Pilot) Aldo Maggioni Discussants Walter Paulus, Franck Flachskampf15.20-16.00 Break 16.00-17.40 Session V: Extracellular matrix Chair: Javier Díez, Gerasimos Filippatos16.00-16.20 Inflammation and matrix regulation in HFPEF Carsten Tschöpe16.20-16.40 Biomarkers of extracellular matrix turnover in LVH and HFPEF Faiez Zannad16.40-17.00 Collagen and new biomarkers Kenneth McDonald17.00-17.20 The matricellular proteins osteoglycin and osteonectin regulate matrix maturation and cardiac function Stephane Heymans184.108.40.206 Looking for new therapeutic targets of myocardial fibrosis in HFPEF. From the bench to the bedside Javier Diez Discussants Michael Frenneaux, Dirk J. Duncker18.00-20.00 "MEDIA" Discussion / Posters Sunday 25th September 08.00-10.00 Sesssion VI: New directions Chair: Carsten Tschöpe, Ajay Shah08.00-08.20 Diastolic dysfunction in diabetes mellitus: The dawn of cardiometabolic continuum Petar Seferovic08.20-08.40 Salvaging the diabetic heart with endothelial factors Giles de Keulenaer08.40-09.00 Pulmonary hypertension in HFPEF Marco Guazzi09.00-09.20 Revealing diastolic dysfunction in mice, a lesson from MRI in vivo Stefan Chlopicki09.20-09.40 Exercise-induced diastolic and systolic dysfunction in HFPEF – mechanisms and implications Michael Frenneaux Discussants Thomas Eschenhagen, Ludwig Neyses10.00-10.10 Break 10.10-12.40 Session VII: Therapy Chair: Walter Paulus, Faiez Zannad10:10-10:30 Beta blockers in HFPEF Andrew Coats10.30-10.50 HFPEF and stem cells Fida Grynspan10.50-11.10 Cell therapy for the failing heart: from gene to protein Stephane Heymans11.10-11.30 Exercise as therapeutic intervention in HFPEF Burkert Pieske11.30-11.50 Meta-analysis on medical therapy Thomas H. Marwick11.50-12.10 Why have HFPEF clinical trials failed so far? Scott Solomon Discussants Stefan Chlopicki and Burkert Pieske12:30-12.40 Summary and Conclusions Burkert Pieske, Zoltán Papp
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved